Expression And Its Significance Of CD82/KAI1 And CD9/MRP-1 In Glioma Cell Lines

Objective: Glioma is one of the serious diseases which threat human beings, and one of the most common primary intracranial tumors. In recent years, morbidity and mortality rates of gliomas were significantly increased at home and abroad, their highly malignant and the prognosis are very poor. Glioma cells them exceptional local invasion and metastasis are enormous challenges of the disease course of treatment. Studies have shown that inhibitors of tumor metastasis by testing can predict prognosis of the situation, even for gene therapy of gliomas theoretical basis for potential targets. Studies have also shown that CD82/KAI1, CD9/MRP-1 play important roles in the many entities of tumor metastasis and proliferation. To further study the CD82/KAI1, CD9/MRP-1 in glioma cell migration and proliferation of the role, this paper differ in two malignant glioma cell lines (CHG-5, U251) for the study, using cell culture, immunocytochemistry, PT-PCR methods such as mRNA and protein levels from the initial detection of CD82/KAI1, CD9/ MRP-1 expression, in order to explore the relationship between the ability of tumor cell migration and proliferation and its expression. Methods: 1. Immunocytochemistry was observed CHG-5, U251 in CD82/KAI1, CD9/MRP-1 expression; 2. RT-PCR was observed CHG-5, U251 in CD82/KAI1mRNA, CD9/MRP-1mRNA expression; 3. 1:100, 1:200 CD82/KAI1 antibody were set up in the intervention group and control group, by wound healing in 24h, 48h observation CD82/KAI1 ability of cell migration and statistical analysis; 4. 1:100, 1:200, 1:400 CD9/MRP-1 antibody were set up in the intervention group and control group, by flow cytometry at 24h, 48h CD9/MRP-1 observed on the cell cycle and statistical analysis.Results: 1. The expression level of CD82 / KAI1 protein and CD9/MRP-1 protein in U251 cell group was higher than that in CHG-5 cells, the difference was significant (P < 0.01); 2.The expression level of CD82/KAI1mRNA and CD9/MRP-1 mRNA in U251 cell group was higher than that in CHG-5 cells, the difference was significant (P<0.01); 3.The number of migrated cells in U251 cell group which be intervened by CD82/KAI1 antibody were higher than that in their control group (P<0.05), and the number of migrated cells with the antibody concentration increased (P< 0.05); 4. Cell cycle arrest in G0/G1 phase in CHG-5 cell group which be intervened by CD9/MRP-1 antibody, difference compared with the control group(24h:P<0.05;48h:P<0.01), and the proportion increased with antibody concentration(P<0.05); 5. Cell cycle arrest at S phase in U251 cell group which be intervened by CD9/MRP-1 antibody, difference compared with the control group(24h:P<0.01;48h:P<0.01), and the proportion increased with antibody concentration(P<0.05).Conclusions : CD82/KAI, CD9/MRP-1 expressed in malignant glioma cell lines, and both in U251 cells compared with CHG-5 cells are high;CD82/KAI1 inhibits U251 cell migration, CD9 / MRP-1 can inhibit CHG-5 cells and U251 cell proliferation;We speculate CD82/KAI, CD9/MRP-1 clinical testing will contribute to glioma treatment options and prognosis.